KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables - Net: 2010-2024

Historic Receivables - Net for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $113.3 million.

  • Pacira BioSciences' Receivables - Net rose 14.52% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 14.52%. This contributed to the annual value of $113.3 million for FY2024, which is 7.34% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Receivables - Net is $113.3 million, which was up 7.34% from $105.6 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Receivables - Net ranged from a high of $113.3 million in FY2024 and a low of $53.0 million during FY2020.
  • Its 3-year average for Receivables - Net is $105.8 million, with a median of $105.6 million in 2023.
  • Data for Pacira BioSciences' Receivables - Net shows a peak YoY surged of 81.57% (in 2021) over the last 5 years.
  • Over the past 5 years, Pacira BioSciences' Receivables - Net (Yearly) stood at $53.0 million in 2020, then skyrocketed by 81.57% to $96.3 million in 2021, then rose by 2.16% to $98.4 million in 2022, then climbed by 7.28% to $105.6 million in 2023, then climbed by 7.34% to $113.3 million in 2024.